Association between C-reactive protein concentration and chronic obstructive pulmonary disease: A systematic review and meta-analysis

Journal of International Medical Research

Volumn 40, Issue 5, 2012, Pages 1629-1635

  Zhang, Y ^a,b   Bunjhoo, H ^a   Xiong, W ^a   Xu, Y ^a   Yang, Danlei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Meta analysis; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; META ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY ANALYSIS; SMOKING; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; METABOLISM;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84880321134     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000501     Document Type: Review

References (30)

1. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765–773.
2. Garcia-Rio F, Miravitlles M, Soriano JB, et al, for the EPI-SCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010; 11: 63.
3. Biljak VR, Pancirov D, Cepelak I, et al: Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets 2011; 22: 466–470.
4. Schols AM, Buurman WA, Staal van den Brekel AJ, et al: Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819–824.
5. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902–907.
6. Margretardottir OB, Thorleifsson SJ, Gudmundsson G, et al: Hypertension, systemic inflammation and body weight in relation to lung function impairment–an epidemiological study. COPD 2009; 6: 250–255.
7. Man SF, Connett JE, Anthonisen NR, et al: Creactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849–853.
8. Dahl M, Vestbo J, Lange P, et al: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250–255.
9. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
10. Larsson SC, Orsini N, Wolk A: Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010; 303: 1077–1083.
11. Aaron SD, Vandemheen KL, Ramsay T, et al: Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res 2010; 11: 41.
12. Amer MS, Wahba HM, Ashmawi SS, et al: Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease. Lung India 2010; 27: 225–229.
13. Foschino Barbaro MP, Carpagnano GE, Spanevello A, et al: Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 2007; 20: 753–763.
14. Bircan A, Gokirmak M, Kilic O, et al: C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 2008; 17: 202–208.
15. Hacker S, Lambers C, Hoetzenecker K, et al: Elevated HSP27, HSP70 and HSP90α in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab 2009; 55: 31–40.
16. He Z, Chen Y, Chen P, et al: Local inflammation occurs before systemic inflammation in patients with COPD. Respirology 2010; 15: 478–484.
17. Van Helvoort HA, Heijdra YF, Thijs HM, et al: Exercise-induced systemic effects in musclewasted patients with COPD. Med Sci Sports Exerc 2006; 38: 1543–1552.
18. Karadag F, Kirdar S, Karul AB, et al: The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19: 104–108.
19. Kersul AL, Iglesias A, Ríos Á, et al: Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011; 47: 176–183.
20. Liu X, Ji Y, Chen J, et al: Circulating visfatin in chronic obstructive pulmonary disease. Nutrition 2009; 25: 373–378.
21. Mannino DM, Ford ES, Redd SC: Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758–762.
22. Petersen AM, Mittendorfer B, Magkos F, et al: Physical activity counteracts increased wholebody protein breakdown in chronic obstructive pulmonary disease patients. Scand J Med Sci Sports 2008; 18: 557–564.
23. Pinto-Plata VM, Müllerova H, Toso JF, et al: Creactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23–28.
24. Tilemann L, Gindner L, Meyer F, et al: Differences in local and systemic inflammatory markers in patients with obstructive airways disease. Prim Care Respir J 2011; 20: 407–414.
25. Undas A, Kaczmarek P, Sladek K, et al: Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176–1182.
26. Vogiatzis I, Stratakos G, Simoes DC, et al: Effects of rehabilitative exercise on peripheral muscle TNFα, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax 2007; 62: 950–956.
27. Yasuda N, Gotoh K, Minatoguchi S, et al: An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998; 92: 993–999.
28. Eagan TM, Ueland T, Wagner PD, et al: Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J 2010; 35: 540–548.
29. Folchini F, Nonato NL, Feofiloff E, et al: Association of oxidative stress markers and Creactive protein with multidimensional indexes in COPD. Chron Respir Dis 2011; 8: 101–108.
30. Núñez B, Sauleda J, Antó JM, et al, for the PACCOPD Investigators: Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183: 1025–1031.